Literature DB >> 19034447

Central and peripheral nervous system toxicity of common chemotherapeutic agents.

Chrissa Sioka1, Athanassios P Kyritsis.   

Abstract

Central and peripheral nervous system toxicity are frequent complications of most chemotherapy regimens, often leading to reduction of dosages or cessation of the responsible drugs. However, sometimes the afflicted toxicity may not be reversible, especially if it is not recognized early, further compromising the quality of life of the cancer patients. The most common chemotherapeutic agents that might cause CNS toxicity manifested as encephalopathy of various severities include methotrexate, vincristine, ifosfamide, cyclosporine, fludarabine, cytarabine, 5-fluorouracil, cisplatin and the interferons (alpha > beta). Involvement of the peripheral nervous system manifested as distal peripheral neuropathy results after therapy with cisplatin, vincristine, taxanes, suramin and thalidomide. Although several compounds have been proposed as neuroprotective agents, few have been shown to be active against the chemotherapy induced neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19034447     DOI: 10.1007/s00280-008-0876-6

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  60 in total

1.  Atypical diffusion-restricted lesion in 5-Fluorouracil encephalopathy.

Authors:  W-W Lee; J-S Kim; K R Son; H-M Kwon
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-08       Impact factor: 3.825

Review 2.  Neurologic complications of cancer and its treatment.

Authors:  Pierre Giglio; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

3.  Treatment-related side effects and quality of life in cancer patients.

Authors:  Eva Mazzotti; Gian Carlo Antonini Cappellini; Stefania Buconovo; Roberto Morese; Alessandro Scoppola; Claudia Sebastiani; Paolo Marchetti
Journal:  Support Care Cancer       Date:  2012-01-21       Impact factor: 3.603

4.  Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity.

Authors:  Mohammad A Rattu; Neal Shah; Jessica M Lee; Antony Q Pham; Nino Marzella
Journal:  P T       Date:  2013-12

5.  Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.

Authors:  Mohamed O Abdalla; Prasanthi Karna; Hari Krishna Sajja; Hui Mao; Clayton Yates; Timothy Turner; Ritu Aneja
Journal:  J Control Release       Date:  2010-11-01       Impact factor: 9.776

6.  Effects of thioTEPA chemotherapy on cognition and motor coordination.

Authors:  Tyler C Alexander; Frederico Kiffer; Thomas Groves; Julie Anderson; Jing Wang; Abdallah Hayar; Michelle T Chen; Analiz Rodriguez; Antiño R Allen
Journal:  Synapse       Date:  2019-03-14       Impact factor: 2.562

7.  Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11).

Authors:  Susan J Zunino; David H Storms; Jonathan M Ducore
Journal:  Cancer Lett       Date:  2010-04-09       Impact factor: 8.679

8.  The Neuroprotective Effect of Mesna on Cisplatin-Induced Neurotoxicity: Behavioral, Electrophysiological, and Molecular Studies.

Authors:  Somayeh Noroozzadeh; Hedieh Esmaeili; Hakimeh Saadati; Keyvan Amirshahrokhi; Javad Shadman; Ali Niapour
Journal:  Neurotox Res       Date:  2020-11-20       Impact factor: 3.911

9.  Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial.

Authors:  Daniel J Zheng; Xiaomin Lu; Reuven J Schore; Lyn Balsamo; Meenakshi Devidas; Naomi J Winick; Elizabeth A Raetz; Mignon L Loh; William L Carroll; Lillian Sung; Stephen P Hunger; Anne L Angiolillo; Nina S Kadan-Lottick
Journal:  Cancer       Date:  2017-11-07       Impact factor: 6.860

Review 10.  Imaging 'the lost tribe': a review of adolescent cancer imaging. Part 2: imaging of complications of cancer treatment.

Authors:  I Zerizer; P D Humphries
Journal:  Cancer Imaging       Date:  2009-11-06       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.